231 related articles for article (PubMed ID: 33452110)
1. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events.
Dang A; Vallish BN; Dang S
Indian J Med Ethics; 2020; V(3):202-207. PubMed ID: 33295289
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Zekarias A; Watson S; Vidlin SH; Grundmark B
Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19.
Kaur A; Chaudhary G; Singh P; Arora S; Kaur R
Curr Drug Targets; 2021; 22(13):1536-1547. PubMed ID: 33371833
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
Montastruc F; Thuriot S; Durrieu G
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2835-2836. PubMed ID: 32721580
[TBL] [Abstract][Full Text] [Related]
9. Audio Interview: New Data on Remdesivir in Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
[No Abstract] [Full Text] [Related]
10. Remdesivir (Veklury) for COVID-19.
Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491
[No Abstract] [Full Text] [Related]
11. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
13. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S
N Engl J Med; 2021 Feb; 384(6):497-511. PubMed ID: 33264556
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.
Wang M; Wu T; Zuo Z; You Y; Yang X; Pan L; Hu Y; Luo X; Jiang L; Xia Z; Deng M
BMJ Support Palliat Care; 2021 Mar; 11(1):45-52. PubMed ID: 32958501
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.
Aït Moussa L; Tebaa A; Alj L; Sefiani H; Meski FZ; Khattabi A; Soulaymani Bencheikh R
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3847-3856. PubMed ID: 37358793
[TBL] [Abstract][Full Text] [Related]
16. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System.
Sun J; Deng X; Chen X; Huang J; Huang S; Li Y; Feng J; Liu J; He G
Clin Pharmacol Ther; 2020 Oct; 108(4):791-797. PubMed ID: 32324898
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients.
Exquis N; Dionisi B; Samer CF; Rollason V; Curtin F; Zekry D; Graf C; Prendki V; Ing Lorenzini K
Viruses; 2024 May; 16(6):. PubMed ID: 38932157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
